Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.

@article{Cheloff2020EmapalumabFT,
  title={Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.},
  author={Abraham Z. Cheloff and Hanny Al‐Samkari},
  journal={Drugs of today},
  year={2020},
  volume={56 7},
  pages={
          439-446
        }
}
Emapalumab-Igsz (Gamifant) is a human monoclonal antibody directed against interferon-γ (IFN-γ), and the first Food and Drug Administration (FDA)-approved therapy for primary hemophagocytic lymphohistiocytosis (HLH). HLH is a disorder characterized by hypercytokinemia in the setting of unbridled immune activation, and emapalumab represents the first therapeutic developed to address the underlying pathophysiology of HLH. Emapalumab is approved for treatment of primary HLH that is refractory… 
Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis: Case Report and the Review of the Literature
TLDR
A 35-year-old man diagnosed with multifocal PG and hemophagocytic lymphohistiocytosis (HLH) with fatal outcome is demonstrated, despite combined, long-term, intensive dermatological and hematological treatment with high doses of steroids, cyclosporin, intravenous immunoglobulins (IVIG), HLH-2004 protocol with intravenously administered etoposide, and anakinra.
Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm
TLDR
The recent views on the involvement of chemokines and selected cytokines in CO VID-19 and the therapeutics currently in clinical development targeting or interfering with them are presented, discussing their potentials in the treatment of COVID-19 infections.